Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on June 26, 2026 by admin
<![CDATA[New phase 3 analyses show centanafadine improves adult ADHD executive function and emotional regulation beyond core symptoms, as FDA review advances toward July 2026.]]>
CategoriesUncategorized TagsADHD, Clinical trial, Cognitive focus and executive control, News Approved

Post navigation

Previous PostPrevious Intravesical CAR T-Cell Therapy Reduces Bladder Cancer Growth in Preclinical Model
Next PostNext Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.